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ABSTRACT
Objectives: This priority setting partnership was
commissioned by Parkinson’s UK to encourage people
with direct and personal experience of the condition to
work together to identify and prioritise the top 10
evidential uncertainties that impact on everyday
clinical practice for the management of Parkinson’s
disease (PD).
Setting: The UK.
Participants: Anyone with experience of PD
including: people with Parkinson’s (PwP), carers,
family and friends, healthcare and social care
professionals. Non-clinical researchers and employees
of pharmaceutical or medical devices companies were
excluded. 1000 participants (60% PwP) provided ideas
on research uncertainties, 475 (72% PwP) initially
prioritised them and 27 (37% PwP) stakeholders
agreed a final top 10.
Methods: Using a modified nominal group technique,
participants were surveyed to identify what issues for
the management of PD needed research. Unique
research questions unanswered by current evidence
were identified and participants were asked to identify
their top 10 research priorities from this list. The top
26 uncertainties were presented to a consensus
meeting with key stakeholders to agree the top 10
research priorities.
Results: 1000 participants provided 4100 responses,
which contained 94 unique unanswered research
questions that were initially prioritised by 475
participants. A consensus meeting with 27
stakeholders agreed the top 10 research priorities. The
overarching research aspiration was an effective cure
for PD. The top 10 research priorities for PD
management included the need to address motor
symptoms (balance and falls, and fine motor control),
non-motor symptoms (sleep and urinary dysfunction),
mental health issues (stress and anxiety, dementia and
mild cognitive impairments), side effects of
medications (dyskinesia) and the need to develop
interventions specific to the phenotypes of PD and
better monitoring methods.
Conclusions: These research priorities identify crucial
gaps in the existing evidence to address everyday
practicalities in the management of the complexities
of PD.
INTRODUCTION
Ensuring that research is effective in addres-
sing the needs of patients and the clinicians
treating them is critically important. The
research agenda has been accused of being
overly inﬂuenced by the pharmaceutical and
medical devices industries,1–3 and of not
addressing the questions about treatments
that are of greatest importance to patients,
their carers and clinicians.4–6 Research needs
to focus on whether treatments are doing
more harm than good, or whether one treat-
ment is better than another, and ensure the
outcomes reﬂect issues that have impact on
the patient’s well-being and participation.7–9
Strengths and limitations of this study
▪ A key strength of this priority setting partnership
was that 1000 people with Parkinson’s, their
carers and healthcare and social care profes-
sionals identified everyday issues which currently
lack firm evidence to direct their management.
▪ In total, 475 participants prioritised these uncer-
tainties, and 27 key stakeholders agreed the top
10 research priorities for the management of
Parkinson’s disease during a final consensus
meeting.
▪ Very few participants were from minority ethnic
populations or living in care homes which could
limit the generalisability of these priorities to
these populations.
▪ The top 10 research priorities for Parkinson’s
disease management were identified by a wide
range of people affected by the disease. These
included the need to address motor symptoms,
non-motor symptoms, mental health issues, side
effects of medications and the need to develop
interventions specific to the phenotypes of
Parkinson’s disease and better monitoring
methods.
▪ It is hoped that this top 10 will lead to future
research that will address issues of importance
for the clinical management of Parkinson’s
disease.
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Treatment uncertainties are deﬁned as questions
about the effectiveness of treatments which are not
adequately answered by systematic reviews of existing
research evidence.10 The James Lind Alliance11 ( JLA)
was established to encourage collaboration between
patients and clinicians to ensure that uncertainties that
impact on everyday clinical practice are addressed in
research. One of JLA’s approaches is priority setting
partnerships12 which aim to identify the top 10 research
priorities in a given area from the perspectives of
patients, carers and healthcare professionals. These
research priorities can then inform research funding
strategies and policies.13
A number of research funders have indicated that they
wish to incorporate the ﬁndings of priority setting part-
nerships into their prioritisation processes.13 Parkinson’s
UK14 identiﬁed four priority research areas with the spe-
ciﬁc aim to ﬁnd a cure for Parkinson’s disease (PD). This
project expands this initial work and identiﬁes the top 10
research priorities for the management of PD.
METHODS
The project was led by Parkinson’s UK, with the
University of East Anglia and the University of
Birmingham acting as academic partners. The JLA pro-
vided an independent chair, advised on the methodology,
and facilitated the process. The project was instigated by
Parkinson’s UK’s Research Support Network15 who
tasked the steering group to oversee the project.
Ethics and data protection
We took advice from the National Research Ethics
Service16 who advised that priority setting partnerships
are service evaluations and therefore did not need
approval from an NHS ethics committee. The reasoning
was that we were asking about research preferences and
research is a ‘standard’ part of NHS treatment proto-
cols.17 Therefore, the project recruited participants via
multiple routes including direct from the NHS. It was
assumed that any participants able to complete the
survey had sufﬁcient mental competence to take part in
the project. Our safeguarding expert (BP) provided
advice on any responses that raised concerns in relation
to the responses provided.
Participants could answer the initial survey anonymously.
Participants who provided their contact details were recon-
tacted for the prioritisation survey. Respondents’ personal
details were kept by Parkinson’s UK in line with the Data
Protection Act, and the UEA team were provided with an
anonymised database of responses.
The priority setting partnership stages
This method is summarised in ﬁgure 1.
Initiation
The ﬁrst stage involved the identiﬁcation of potential
partner organisations which provided access to a wide
range of participants. Anyone living in the UK with
experience and understanding of living with PD was eli-
gible to participate in the identiﬁcation of uncertainties
and their prioritisation. This included: people with
Parkinson’s (PwP); carers and former carers; family
members and friends; healthcare and social care profes-
sionals who work, or have worked, with people living
with the condition. Non-clinical researchers and employ-
ees of pharmaceutical or medical devices companies
were excluded from the survey.
Consultation
The steering group had a broad spectrum of representa-
tives and they identiﬁed the scope of the priority setting
partnership. All aspects of the management of PD such
as healthcare, surgery, rehabilitation, medication, com-
plementary therapies, nutrition, carer support, service
provision and design were included. Excluded issues
were curative therapies, prevention, diagnostic tests, aeti-
ology, epidemiology and prognosis. Curative and pre-
ventive therapies were agreed to be those that halted or
reversed the neurodegenerative processes seen in PD. It
was agreed that the overarching research aspiration was
an effective cure for PD, and that the speciﬁcs of how
this could be addressed had been identiﬁed previously
by Parkinson’s UK.14
A simple survey was created that asked about four
areas where respondents would like to see issues
answered by research: the symptoms of PD; day-to-day
life with PD; the treatment of PD; anything else.
The exact phrasing of the survey was reﬁned after a
pilot survey involving 57 PwP and 20 carers, in order to
ensure clarity of meaning and encourage the generation
of relevant responses. A copy of the ﬁnal version of the
survey is provided in online supplementary material.
Participants were invited to complete the survey on the
Parkinson’s UK website or by post. Parkinson’s UK adver-
tised the study in their membership magazine which goes
out to more than 35 000 people affected by Parkinson’s,
on their website and targeted relevant groups at meetings
and conferences including: 13 Parkinson’s UK regional
events, PD Nurse Specialists Association conference 2013,
British Movement Disorders Group (BritMODIS)
Conference 2014, National Parkinson’s UK Research
Supporters Conference 2013, Oxford Parkinson’s Disease
Centre Open Day 2013, South West Research Supporters
day (Bristol), North West information day (St Helens).
Parkinson’s UK also advertised the project directly to
centres of clinical excellence throughout the country, the
Tracking Parkinson’s centres18 and the Oxford
Parkinson’s Disease Centre.
We contacted relevant charities such as Cure
Parkinson’s UK, the Alzheimer’s Society and the
Alzheimer’s Research Trust who promoted participation
of their members via ﬂyers, magazine articles and social
media. We contacted professional groups with an interest
in PD such as The British Geriatrics Society, The
Specialist Section for Neurological Practice at the College
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of Occupational Therapists, PD Specialist Interest Group
of the Royal College of Speech and Language Therapists
and the Parkinson’s Nurse Specialists Association. We
contacted the National Institute for Health Research’s
Dementias and Neurodegeneration (DeNDRoN)19
Specialty Clinical Research Network and the Enabling
Research In Care Homes group (ENRICH)20 in order to
ask them to encourage participation in the survey by
neurological clinicians and the care home sector and
residents. We used Parkinson’s UK’s database of people
from black and minority ethnic populations who have an
interest in PD to enhance our outreach to these commu-
nities. When sending out the survey we noted that we
could take responses over the phone and provide a trans-
lation service if needed. Representatives from Parkinson’s
UK visited a couple of movement disorder clinics to
promote the survey.
Collation
The ‘raw’ treatment uncertainties were entered onto the
database verbatim.
Statements not associated with management uncer-
tainties were coded as being ‘out of remit’. In order to
maximise the value of respondents’ comments we also
coded ‘treatment dissatisfactions’ where we were
provided with information regarding poor treatment
provision. These were shared with Parkinson’s UK’s
Policy and Service Improvement and Professional
Engagement and Education departments in order for
them have anonymised anecdotes to demonstrate the
impact of poor care on PwP.
The Cochrane Library, MEDLINE, EMBASE,
CINAHL, PsychInfo were searched from inception to
January 2014 for systematic reviews of interventions for
the management of Parkinson’s. The major systematic
review’s certainties were agreed by the core team
(KHOD, CEC, CS, DJD, RP and HF) before the submis-
sions were received. However, all submissions were
checked subsequently against the evidence base to deter-
mine if there were any further certainties in unantici-
pated areas. Submissions which related to management
certainties were labelled as ‘evidence found’ and for-
warded to Parkinson’s UK as this assisted in the identiﬁ-
cation of a lack of knowledge of effective treatments,
and so demonstrated a need for education.
In order to standardise the format each uncertainty
was transformed into population, intervention, compara-
tor and outcome (PICO) format by the coding team
(KHOD, DJD, RP and HF). The coding team met fort-
nightly to discuss coding issues and ensure consistency.
Figure 1 Flow chart of methods
(F&F, family and friends; HSCP,
health and social care
professionals; PwP, people with
Parkinson’s; PICO, population,
intervention, comparator and
outcome).
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KHOD double checked the coding of the majority of
the statements to ensure consistency. Respondents were
able to provide multiple statements in response to each
of the four prompts (the symptoms of PD; day-to-day life
with PD; the treatment of PD; anything else). Frequently
we derived more than one PICO question from a single
statement. The PICO questions were expressed as indi-
vidual research questions, which were then assembled
and duplicates combined. The frequency of duplicated
uncertainties was recorded. The resulting PICO ques-
tions were checked again against the evidence base by
KHOD, CEC and CS.
Prioritisation
The steering group met to examine the uncertainties
identiﬁed. Uncertainties were checked for speciﬁcity in
order that they could be adequately investigated and
were phrased in a manner understandable to partici-
pants. Uncertainties with less than three duplicate sub-
missions were considered for exclusion. This was in
order to reduce the number of uncertainties for priori-
tisation to a manageable level, and is recommended by
the JLA’s methodology.12
The ﬁnal set of uncertainties were then sent to partici-
pants who had provided their contact details and to the
members of the Research Support Network.15 It was also
advertised in an article in the Parkinson’s UK member-
ship magazine and promoted through social media.
Participants were asked to read the list of uncertainties
and identify their own top 10 priorities. A copy of the
survey is provided in online supplementary materials.
The ratings for each uncertainty statement were scored
in reverse, that is, a priority rated ﬁrst would have 10
points assigned. These were then summated and divided
by the number of respondents from each group of parti-
cipants (PwP, carers, family and friends, and profes-
sionals) and ranked in order of priority. These four sets
of ratings were then added together and again ranked to
identify the top 26 for all participants. The top 26 uncer-
tainties were chosen because the experience of the
JLA12 is that this is a sufﬁcient number of uncertainties
to identify the top 10, and in order to be able to label
them A–Z.
The ﬁnal consensus meeting to agree the top 10
research priorities involved participants from a range of
populations impacted by PD and used consensus-
reaching decision-making methods. Prior to the meeting
participants were asked to prioritise the top 26 uncer-
tainties which were presented in random order and
labelled A–Z.
At the ﬁnal workshop, ground rules were agreed
about keeping participants’ opinions and disclosures
conﬁdential to the workshop participants alone and
respecting alternative viewpoints. The process’ intent
was to identify a set of prioritised recommendations
while preventing the domination of the discussions by a
single person and encouraging quieter group members
to participate. Expectations were managed by
highlighting that consensus meant that people were
unlikely to leave the meeting with all of their views
being represented in the top 10, and that compromise
would be necessary.
Participants were divided into three groups with
mixed representation and led by an independent chair-
person from JLA and two facilitators from Parkinson’s
UK. Participants were asked to prioritise all 26 uncer-
tainties which were printed onto A4 cards. Where there
was disagreement about the level of priority, each card
had the interim prioritisation for each group (PwP,
carers, family and friends, and professionals) written on
the back, and this information assisted decisions about
rankings. The three sets of rankings were combined.
Participants were then divided into three different
groups, again with mixed representation. In the second
round they were presented with the joint prioritisation
from round one and focused mainly on identifying
whether the correct uncertainties were in the top 10,
and had the right prioritisation. The three groups’ prior-
itisations were combined and the ﬁnal top 15 presented
in a ﬁnal round to the entire group. The ﬁnal group was
reminded that all of the uncertainties presented had
insufﬁcient evidence at present to inform clinical prac-
tice. In the ﬁnal round participants reached consensus
on which items should be in the top 10.
Databases
The complete list of all of the uncertainties identiﬁed
was prepared and formatted for inclusion in the UK
Database of Uncertainties about the Effects of
Treatments (UK DUETs).10 This will allow researchers to
examine the all of the research uncertainties identiﬁed
in this project.
A searchable database of the anonymised responses of
the participants regarding their concerns about the
management of PD will be made available to researchers
via Parkinson’s UK. This will allow researchers to include
quotes that highlight the impact of a particular issue on
PwP in their grant applications and research.
RESULTS
Steering group
The project’s steering group consisted of representatives
from Parkinson’s UK (n=8), and the Cure Parkinson’s
Trust (n=1), PwP (n=2), carers (n=2), clinical consul-
tants (n=2) and a PD nurse specialist (n=1). Those from
Parkinson’s UK included representatives with expertise
in research development, policy and campaigns (n=5),
information and support worker services (n=1), advisory
services (n=1) and resources and diversity (n=1).
Consultation
Respondents could provide more than one uncertainty
for each of the four areas asked about (the symptoms of
PD; day-to-day life with PD; the treatment of PD; any-
thing else). Hence 1000 participants generated 4100
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responses which contained 2632 research uncertainties,
of which 112 were unique (ﬁgure 2). Around 40% of
responses were returned by post (n=397), the remainder
were submitted online. No one used the translation
service, but a representative from Parkinson’s UK did
assist some PwP recruited in movement disorders clinics
to complete the form when they had limited English
literacy.
The 600 respondents with PD mostly lived at home
either with support from carers or family (51%), or
independently (41%), 1% lived in nursing or residential
accommodation (the remainder were in other accom-
modation or did not respond; table 1). Professionals
(n=140) consisted of consultants (24%), PD nurse spe-
cialists (19%), nurses and care assistants (9%), allied
health professionals (31%), social workers (1%) and
others (16%). Thirty-one respondents classiﬁed them-
selves as ‘other’ and seven respondents did not provide
information on their role.
Research certainties
The academic team agreed a priori that monotherapy
with levodopa, dopamine agonists, catechol-O-methyl
transferase (COMT) inhibitors, monoamine oxidase B
(MAOB) inhibitors and anticholinergics all have evi-
dence of efﬁcacy with motor symptoms, at the expense
of side effects.21–25 The evidence is mostly from short
term studies so longer term efﬁcacy and adverse effects
are uncertain. There is no good evidence regarding the
optimal time for treatment initiation or dosage increase.
A recent very large randomised controlled trial did show
very small but persistent beneﬁts for patient-rated mobil-
ity scores when treatment is initiated with levodopa com-
pared with levodopa-sparing therapy.26
For the treatment of motor complications with
adjuvant therapies, the evidence supports that levodopa
plus dopamine agonists, or COMT-inhibitors or MAOB-
inhibitors all reduce patients’ off-time, reduce the
required L-dopa dose, and improve motor and activities
Figure 2 Flow chart of
responses.
Table 1 Table of participant characteristics
People with
Parkinson’s Carers
Family and
friends
Number 600 136 86
Median age range 65–74 65–74 55–64
Ethnicity (%)
White 86 90 90
Black or Asian 5 1 7
Other 2 1 2
Not stated 7 8 1
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of daily living scores in PwP with motor complications
on L-dopa.27 Again, the evidence is mostly from short
term studies so longer term efﬁcacy and adverse effects
are uncertain. Which adjuvant drug is best is mostly
uncertain, although the MAOB-inhibitor tolcapone
overall has greater efﬁcacy than entacapone but is asso-
ciated with a worse adverse event proﬁle. For the small
subset of PwP able to tolerate deep brain stimulation
(DBS) (estimated at 1–10%),28 DBS to the subthalmic
nucleus improves self-reported quality of life and
reduces motor complications of PD up to 2 years when
compared to best treatment with medications but at a
higher risk of severe adverse events.29 Physiotherapy has
short term beneﬁts in PD (up to 3 months), but there is
no evidence regarding the best sort of physiotherapy.30
Unfortunately there is insufﬁcient research evidence for
any ‘certainties’ in speech therapy31 32 and occupational
therapy33 for PD.
As a result of checking the uncertainties against
current evidence we identiﬁed evidence to refute a
number of submissions. One respondent suggested that
ethnicity may affect the response to medications;22 27
however anti-Parkinson’s medications have been tested
worldwide and no differences in efﬁcacy or safety have
been noted in relation to ethnicity. Another respondent
suggested that immunosuppression was a side-effect of
rasagaline; this is not a side effect that has ever been
reported for rasagaline.34
As can be seen there are relatively few evidential cer-
tainties to inform the day-to-day management of PD.
Prioritisation
Eighteen uncertainties were excluded from the priori-
tisation by the steering group (although they were still
entered onto the UK DUETS database) as they had less
than three duplicate submissions and were deemed to
be unlikely to be important enough to reach the top 10
priorities. Those statements that did reach the ﬁnal top
10 had a range of 20–83 duplicate submissions.
The 94 uncertainties were then sent to the 409 partici-
pants that had provided their contact details, 302
members of the Research Support Network, and respon-
dents to the magazine article and social media. The 94
uncertainties were prioritised by 475 participants consist-
ing of 342 PwP; 57 carers; 34 friends and family; and 42
health and social care professionals. The top 26 prior-
ities of the four groups were summated, ranked and
labelled A-Z and presented to the ﬁnal prioritisation
workshop (table 2).
The ﬁnal prioritisation workshop to agree the top 10
research priorities (table 3) had 27 participants includ-
ing 10 PwP, 5 carers and family, 5 consultants, 4 PD
nurse specialists and 3 allied health professionals. One
word change was allowed on the fourth uncertainty;
where it was changed from treatments being ‘tailored’ to
‘developed’ to suit phenotypes of PD. This was agreed
with KHOD who had read all of the original responses
that had generated this uncertainty and felt that this
change of wording was still representative of the original
respondents’ intent. Although proposals were made to
combine uncertainties, these were resisted as it was felt
that this would have made the scope of the research
questions too broad.
DISCUSSION
This study has identiﬁed the paucity of evidence cur-
rently available to address the everyday practicalities of
managing a complex disease such as PD. The top 10
research priorities (table 3) included the need to
address motor symptoms (balance and falls, and ﬁne
motor control), non-motor symptoms (sleep and urinary
dysfunction), mental health issues (stress and anxiety,
dementia, and mild cognitive impairments), side effects
of medications (dyskinesia) and the need to develop
interventions speciﬁc to the phenotypes of PD and
better monitoring methods. These results will help
funders identify future priorities for research that have
greatest relevance to patients and the clinicians that
treat them.
The fact that research around balance and falls was
the top priority underscores the frequency of falls in
PwP and the impact falls and fear of falling can have on
more global issues such as function, quality of life and
care home admission.35 Exercise can improve balance,
but reducing falls is more challenging.36 37 Although
medications can improve overall motor performance
which may reduce risk factors for falls, balance and falls
are rarely measured or reported speciﬁcally in medica-
tion trials.22 27 Additionally there may be problems
accessing appropriately trained physiotherapists38 39 and
poor medication adherence40 41 may impact on effect-
iveness. Therefore there is a great need for research for
effective interventions to improve balance and reduce
falls in PwP.
Specificity of research questions
One criticism of Priority Setting Partnerships is that they
generate research questions that are too broad and
vague to inform researchable questions and funder pri-
orities.13 We ensured the uncertainties in this study were
as speciﬁc as possible, and did not allow similar uncer-
tainties to be merged. Each uncertainty was informed by
a number of initial statements, and each one was
phrased so as to represent their overall intent. Therefore
the use of the term ‘treatments’ was intended to cover a
wide range of speciﬁc interventions such as pharmaco-
logical, behavioural and rehabilitation interventions.
Sometimes the lack of speciﬁcity of the question high-
lights the general lack of evidence around the issue. For
example, the 9th uncertainty, ‘improving dexterity’,
might be addressed by current medications but this is
rarely recorded as an outcome in clinical trials.22 27
Occupational therapy interventions might be helpful for
speciﬁc issues, for example, adapted computer mice, but
there is very limited research in this area.33 42 We are
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Table 2 Interim prioritisation of the top 26 uncertainties
Uncertainty
PwP
Score
Carer
Score
F&F
Score
HSCP
Score Total
Interim
rank A–Z ID
What treatments are helpful in reducing tremor in people with Parkinson’s? 93 83 92 91 359 1 T
What treatments are helpful for reducing balance problems and falls in people with Parkinson’s? 92 93 80 94 359 1 E
Is it possible to identify different types of Parkinson’s, eg, tremor dominant? And can we tailor
treatments best according to these different types?
88 88 89 88 353 3 U
What treatments would ensure the medications were equally effective each day (prevented/managed
wearing off, variability, on/off states) in people with Parkinson’s?
89 94 88 81 352 4 H
Would the monitoring of dopamine levels in the body (eg, with blood tests) be helpful in determining
medication timing and amount (dose)?
91 89 86 86 352 4 L
What is helpful for improving the quality of sleep in people with Parkinson’s? 94 79.5 93 84 350.5 6 G
What best treats mild cognitive problems such as memory loss, lack of concentration, indecision and
slowed thinking in people with Parkinson’s?
87 91 77 89.5 344.5 7 D
What treatments are helpful in reducing urinary problems (urgency, irritable bladder, incontinence) in
people with Parkinson’s?
90 77 94 79 340 8 I
What drug treatments are best for the different stages of Parkinson’s? 83 87 87 77.5 334.5 9 X
What approaches are helpful for reducing stress and anxiety in people with Parkinson’s? 75 77 82 92 326 10 M
What treatments are helpful for reducing dyskinesias (involuntary movements, which are a side effect
of some medications) in people with Parkinson’s?
80 90 73.5 77.5 321 11 J
What best treats dementia in people with Parkinson’s? 56 92 75 93 316 12 Z
What interventions are effective for reducing or managing unexplained fatigue in people with
Parkinson’s?
78 65 85 85 313 13 Y
What best helps prevent or reduce freezing (of gait and in general) in people with Parkinson’s? 79 71.5 76 82 308.5 14 O
What treatments are helpful for swallowing problems (dysphagia) in people with Parkinson’s? 66 74.5 81 80 301.5 15 C
What is the best method of monitoring a person with Parkinson’s response to treatments? 81 52.5 83.5 83 300 16 F
What training, techniques or aids are needed for hospital staff, to make sure patients with Parkinson’s
get their medications correctly and on time?
53 86 64.5 89.5 293 17 W
What treatments are helpful in reducing bowel problems (constipation, incontinence) in people with
Parkinson’s?
77 85 90 40 292 18 K
What is the best type and dose of exercise (physiotherapy) for improving muscle strength, flexibility,
fitness, balance and function in people with Parkinson’s?
84 68 64.5 67.5 284 19 Q
Can medications be developed to allow fewer doses per day for people with Parkinson’s? (For
example combinations of medications in one pill, slow release pills)
73 84 56 69 282 20 S
What helps improve the dexterity (fine motor skills or coordination of small muscle movements) of
people with Parkinson’s so they can do up buttons, use computers, phones, remote controls etc?
85 59.5 73.5 54.5 272.5 21 A
What treatments are effective in reducing hallucinations (including vivid dreams) in people with
Parkinson’s?
52 79.5 71.5 61 264 22 P
What is the best treatment for stiffness (rigidity) in people with Parkinson’s? 86 67 63 46 262 23 B
At which stage of Parkinson’s is deep brain stimulation (a surgical treatment that involves implanting a
‘brain pacemaker’ that sends signals to specific parts of the brain) most helpful?
69 59.5 91 42 261.5 24 N
What training to improve knowledge and skills do informal carers (family and friends) need in order to
best care for people with Parkinson’s?
42 82 70 63.5 257.5 25 V
What is the best treatment for pain in people with Parkinson’s? 82 54 60.5 57.5 254 26 R
F&F, family and friends; HSCP, health and social care professionals; PwP, people with Parkinson’s.
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even unsure of the impact of poor ﬁne motor control
and what assessments would best measure not only the
amelioration of the impairment but improvements in
activities and participation.
Links with other research priority projects
A Dutch study43 recently tried to identify patient-relevant
research topics by interviews and focus groups with
57PwP, carers and researchers. These were then priori-
tised by 1360 PwP. The topics covered all areas of PD
research including cure, diagnosis, psychological aspects,
relationships and healthcare. The research topics identi-
ﬁed were broad and their prioritisation unclear. Overall
they reported that research into effective strategies for
living and coping with the disease were the priority of
PwP. Many of the top 10 priorities identiﬁed in this
project could be said to address the need for effective
strategies for living and coping with PD.43 Priority
Setting Partnerships have been previously conducted for
dementia and urinary incontinence.44 45 Although some
of the priorities from these projects might have rele-
vance to PwP they did not prioritise Parkinson’s-speciﬁc
aspects of these conditions. This is almost certainly
because the population of PwP with these problems is
relatively small compared to the overall populations with
these issues.
Risk management
This project raised a number of risk management chal-
lenges which should be considered in the design of
future Priority Setting Partnerships.
We were only able to follow-up safeguarding issues
where participants had provided their contact details.
One response raised concerns about suicidality, and as
we did not have the contact details for this participant,
we had no way to contact the participant to ensure they
had appropriate support. Future Priority Setting
Partnerships should consider making the provision of
contact details mandatory for participants so that issues
like this can be followed up and support offered.
However we recognise that this may inhibit participation,
so it may be considered sufﬁcient to provide participants
with links to appropriate sources of support.
A number of other responses raised concerns about
potential abuse (of both PwP and their carers), lack of
appropriate service provision, and families failing to
cope. We consulted with safeguarding experts who
advised that safeguarding referrals were not appropriate
or necessary but we responded to these participants and
ensured they were aware of the support provided by
Parkinson’s UK. It would be best practice in future to let
participants know in advance that if their responses
cause concern for the research team there is likely to be
some form of follow-up.
In response to the ﬁrst survey, a couple of patients
admitted to taking ‘medication holidays’ or adhering to
their medication regime erratically (eg, every other day)
and it was clear that these patients were unaware of the
risks associated with this.46 As a result of this ﬁnding,
Parkinson’s UK are improving their information leaﬂets
on this issue.
Finally, potential mental health needs of the research
team transforming the responses into PICO questions
and possible needs for support should be considered.
Some of the responses described distressing situations
and team members need to feel that they can discuss
issues that concern them, and take breaks when needed
in order to manage this stress and to obtain appropriate
levels of support.
Study limitations
Although great efforts were made to include participants
from black and minority ethnic and care home popula-
tions we were not very successful at recruiting these
populations. It is also unlikely that those with literacy
issues would participate in a project like this. Most
Table 3 Final prioritised and ranked uncertainties for the management of Parkinson’s disease
Overarching research aspiration: an effective cure for Parkinson’s disease
1 What treatments are helpful for reducing balance problems and falls in people with Parkinson’s?
2 What approaches are helpful for reducing stress and anxiety in people with Parkinson’s?
3 What treatments are helpful for reducing dyskinesias (involuntary movements, which are a side effect of some
medications) in people with Parkinson’s?
4 Is it possible to identify different types of Parkinson’s, eg, tremor dominant? And can we develop treatments to address
these different types?
5 What best treats dementia in people with Parkinson’s?
6 What best treats mild cognitive problems such as memory loss, lack of concentration, indecision and slowed thinking in
people with Parkinson’s?
7 What is the best method of monitoring a person with Parkinson’s response to treatments?
8 What is helpful for improving the quality of sleep in people with Parkinson’s?
9 What helps improve the dexterity (fine motor skills or coordination of small muscle movements) of people with
Parkinson’s so they can do up buttons, use computers, phones, remote controls etc?
10 What treatments are helpful in reducing urinary problems (urgency, irritable bladder, incontinence) in people with
Parkinson’s?
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respondents with PD were likely to be members of char-
ities whose membership tends to be white, middle class
and to have higher levels of education. Therefore the
study results are more likely to be relevant to white PwP
who live in their own homes either independently or
with some assistance. This means that priorities of rele-
vance to people with more severe disease (either pallia-
tive stage PD or with signiﬁcant comorbidities) or to
ethnic minorities may not have been identiﬁed, or if
identiﬁed not given the priority that these populations
would have given if fully represented in this exercise.
Consideration should be given to identify the research
priorities of these groups separately.
Another limitation was the relatively small proportion
of social care professionals (1%) who participated in this
study. It is possible that as this professional group works
mainly outside of healthcare settings they could have
raised different unique research uncertainties.
Theoretically, the exclusion of statements with less
than three duplicate submissions could have introduced
bias. However by keeping the survey as short as possible
we enhanced its accessibility. Also those statements that
did reach the ﬁnal top 10 had a range 20–83 duplicate
submissions, so it is unlikely that a statement with less
than three duplicate submissions would have reached
the ﬁnal top 10.
CONCLUSIONS
This top 10 list of research priorities for the manage-
ment of PD was generated using a systematic, transpar-
ent and inclusive method. The research priorities
covered a wide range of topics of importance to those
affected by the impact of PD; motor symptoms (balance
and falls, and ﬁne motor control), non-motor symptoms
(sleep and urinary dysfunction), mental health issues
(stress and anxiety, dementia, and mild cognitive impair-
ments), side effects of medications (dyskinesia) and the
need to develop interventions speciﬁc to the phenotypes
of PD and better monitoring methods. It is hoped that
the ﬁndings will lead to future research that will address
issues of importance for the clinical management of PD.
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